Everest Organics share price & results
- Jun 2026
- Jun 2026
Telangana-based manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates, a global leader in the prazole segment, now also offering CDMO/CMO contract manufacturing.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 48.4 | −10.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 8.9 | +0.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.1 | −21.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 7.21 | +9.9 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 1.04 | +7.6 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 5.49 | +42.6 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −36.2% 1Y
1Y: ₹401.8 on 24 Oct 2025 → ₹256.4. High ₹522.5 (2 Jan 2026), low ₹203.45 (30 Mar 2026).
- Previous close
- ₹240
- Market cap
- ₹251 Cr
- 52-week range
- ₹203.45 – ₹522.5
- One year
- −38.82%
- Price to earnings (TTM to Jun 2026)
- 47.72×
- Return on equity (TTM to Jun 2026)
- 7.21%
Overview
- Symbol
- NSE:EVERESTO
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Everest Organics Ltd. does
Based on the company's own presentations, annual report and earnings calls.
Everest Organics manufactures Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates at a single USFDA-approved facility in Sangareddy District, Telangana, holding close to 15% of the global prazole market. Its portfolio spans anti-ulcerants (Omeprazole, Esomeprazole, Pantoprazole, Rabeprazole, Dexlansoprazole), an anti-hyperlipidemic (Fenofibrate), an anti-fungal (Itraconazole), an anticoagulant (Rivaroxaban), an antihyperuricemic (Febuxostat) and antivirals (Oseltamivir, Remdesivir). The company also recovers and sells green by-product chemicals from its own manufacturing waste streams, and in FY24-25 expanded into contract development and manufacturing (CDMO/CMO) services for other pharma companies. Products are exported to more than 40 countries with a strong presence across South Asia.
Segments
- APIs & Intermediates manufacturing
- CDMO/CMO contract manufacturing
- By-product green chemicals
- Manufacturing facility
- 1 API plant, Sangareddy District, Telangana — 33 acres total (10 acres built-up, 23 acres green belt)
- Global prazole market share
- ~15% of global prazole market
- Export reach
- 40+ countries, strong presence in South Asia
- Core API portfolio
- 9 APIs (Omeprazole, Esomeprazole, Pantoprazole, Fenofibrate, Dexlansoprazole, Rabeprazole, Itraconazole, Rivaroxaban, Febuxostat) plus antivirals Oseltamivir & Remdesivir
- Regulatory certifications
- cGMP, cGLP, WHO-GMP, USFDA-approved facility; ISO 9001:2015, EMS 14001:2015, OHSAS 18001:2007
- By-product green chemicals recovered
- 10 (e.g. Ammonium Sulphate, Calcium Sulphate, Calcium Nitrate, Sodium Sulphate)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −21% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 44 | 42 | 41 | 54 | 51 | 43 | 49 | 48 |
| Expenses | 41 | 38 | 37 | 49 | 46 | 39 | 42 | 44 |
| Operating profit | 3 | 4 | 3 | 4 | 5 | 4 | 7 | 4 |
| Operating margin | 7.8% | 9.6% | 8.4% | 8.3% | 10.1% | 8.3% | 13.7% | 8.9% |
| Other income | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 |
| Tax rate | 1.3% | 0.9% | −206.3% | 35.2% | 56.9% | 65.4% | −21.2% | 26.8% |
| Net profit | 1 | 1 | 3 | 1 | 1 | 0 | 3 | 1 |
| EPS (₹ per share) | 0.92 | 1.42 | 3 | 1.45 | 1.19 | 0.37 | 2.71 | 1.14 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 183 | 197 | 159 | 196 |
| Expenses | 182 | 186 | 152 | 176 |
| Operating profit | 1 | 11 | 7 | 20 |
| Other income | 7 | 1 | 1 | 1 |
| Interest | 3 | 5 | 5 | 7 |
| Depreciation | 4 | 6 | 6 | 6 |
| Profit before tax | 0 | 1 | -3 | 8 |
| Net profit | -0 | 0 | -1 | 6 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 8 | 8 | 8 | 10 | 10 | 10 |
| Reserves | 39 | 38 | 38 | 60 | 63 | 66 |
| Borrowings | 39 | 51 | 58 | 48 | 49 | 50 |
| Other liabilities | 92 | 105 | 123 | 106 | 115 | 114 |
| Total liabilities | 178 | 202 | 227 | 223 | 237 | 240 |
| Fixed assets | 49 | 54 | 52 | 50 | 49 | 46 |
| Capital work in progress | 8 | 12 | 21 | 23 | 22 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 121 | 136 | 153 | 150 | 166 | 171 |
| Total assets | 178 | 202 | 227 | 223 | 237 | 240 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 14 | 14 | 18 | 16 | -5 | 4 |
| Cash from investing | -12 | -17 | -16 | -13 | -5 | -2 |
| Cash from financing | -2 | 2 | -3 | -3 | 16 | -8 |
| Net cash flow | 0 | -1 | 0 | 0 | 6 | -6 |
| Free cash flow | 7 | -3 | 5 | 3 | -11 | 2 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 102 | 125 | 152 | 185 | 202 | 216 |
| Inventory days | 110 | 110 | 139 | 128 | 166 | 132 |
| Days payable | 183 | 212 | 282 | 324 | 315 | 262 |
| Cash conversion cycle | 29 | 24 | 9 | -11 | 53 | 86 |
| Working capital days | 21 | 9 | -12 | -20 | 3 | 27 |
| Return on capital employed | 34.0% | 6.0% | 4.0% | 6.0% | 2.0% | 12.0% |
| Dividend payout | 9.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 59.60% as of Jun 2026; institutions added 0.00 pts since Mar 2026.
- Promoters 59.60%
- Domestic institutions 0.02%
- Public 40.38%
Who is on the register
Named in the Jun 2026 filing
Every holder of Everest Organics Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 38.37% | unchanged | |
| 16.01% | unchanged | |
| 7.52% | unchanged | |
| 7.44% | −0.09 pp | |
| 2.30% | unchanged | |
| 1.32% | unchanged | |
| 1.16% | unchanged | |
| 1.11% | unchanged | |
| 1.02% | unchanged | |
| 0.58% | unchanged | |
| 0.05% | unchanged | |
| 0.02% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Everest Organics Ltd.
Free account: one company. Everything above stays public.
Write why you follow Everest Organics Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Everest Organics Ltd.
Guides on how to read this kind of business and the numbers that matter.